Physician profile
Michael J Strachan
NPI 1982655445
$158,188.63
in general payments reported to CMS, 2019-2025
49 companies · $2,837 in 2025
The $2,837 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $38K · 2021: $9,206 · 2022: $5,236 · 2023: $2,390 · 2024: $3,491 · 2025: $2,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,459 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,458.85 |
| Education | $259.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $79,630.00 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| United Rheumatology | $28,750.00 | 2019-2021 | |
| Abbvie INC. | $17,885.07 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $11,407.37 | 2019-2024 | Taltz |
| Janssen Scientific Affairs, LLC | $7,655.22 | 2019-2020 | |
| Janssen Biotech, INC. | $1,593.13 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $1,545.17 | 2019-2025 | |
| Ucb, INC. | $1,387.42 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,247.01 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $1,238.12 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $784.96 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $703.07 | 2021-2025 | Saphnelo, Evusheld, Fasenra |
| Glaxosmithkline, LLC. | $464.08 | 2019-2025 | Benlysta |
| Radius Health, INC. | $461.91 | 2019-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $444.08 | 2021-2024 | Acthar |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Strachan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.